EchoSolv HF FDA application update
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Echoiq Limited provides an update on its EchoSolv HF FDA application, indicating ongoing work with regulatory consultants to advance towards FDA clearance. The company believes there is a clear path forward to obtaining this clearance, which could potentially be achieved in the near future. Echoiq is assessing multiple pathways to address the FDA's concerns, including an administrative appeal or a new submission. The company remains committed to collaborating with the FDA to resolve the issues cited in the determination.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from EchoIQ
- Notification regarding unquoted securities - EIQ
- Cleansing Notice
- Application for quotation of securities - EIQ
- Investor Webinar
- Trading Halt
Later from EchoIQ
- Date of AGM and Closing Date for Director Nominations
- EchoSolv HF FDA 510(k) update
- Notification of cessation of securities - EIQ
- Notice of Annual General Meeting/Proxy Form
- Quarterly Activities Report & Appendix 4C Cashflow Report
Follow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ